STOCKS TELEGRAPH

Tag: KTRA stock

  • Kintara Therapeutics (KTRA) Sees Market Recovery Post Friday Downturn

    Shares of Kintara Therapeutics, Inc. (Nasdaq: KTRA) experienced a sluggish trading session on Friday, dipping nearly 5%. However, the pre-market session today hints at a slight rebound, showing a 2% increase.

    Key Corporate Updates

    Kintara, a company specializing in cancer therapies, recently unveiled significant developments:

    1. Initiation of REM-001 Study

      Kintara commenced an open-label study evaluating REM-001 in cutaneous metastatic breast cancer patients. This study, funded primarily by a $2.0 million grant from the National Institutes of Health, aims to optimize treatment protocols before moving to a Phase 3 trial.

    2. Strategic Review Underway

      The company’s Board of Directors initiated a strategic review process to enhance shareholder value, enlisting Ladenburg Thalmann & Co. Inc. as its financial advisor.

    3. Focus Shift to REM-001

      Following preliminary results from the GBM AGILE study, which indicated no significant improvement with VAL-083 in glioblastoma treatment, Kintara redirected its focus to REM-001, discontinuing the development of VAL-083.

    Financial Snapshot

    In its fiscal second-quarter results, ending December 31, 2023, Kintara reported:

    • Cash and cash equivalents of approximately $0.7 million as of December 31, 2023.
    • Net proceeds of approximately $6.1 million from the sale of common stock in early 2024.
    • A net loss of approximately $1.0 million for the three months ended December 31, 2023, attributed to lower research and development expenses and reduced general and administrative costs.

    Market Dynamics

    Recent market activity has garnered attention towards Kintara’s stock. Notable spikes in trading volume and positive indicators have piqued investor interest. The successful completion of an ATM facility, along with strengthened shareholder equity and the absence of trading constraints, further augments market sentiment.

    Conclusion

    Kintara Therapeutics navigates a dynamic market environment with strategic maneuvers and promising developments in its product pipeline. Despite encountering recent hurdles, the company’s proactive initiatives and favorable market dynamics position it for potential growth. Investors remain vigilant as Kintara advances its mission to pioneer innovative cancer therapies.

  • Kintara Therapeutics, Inc. (KTRA) stock is going down – Learn more about it!

    Kintara Therapeutics, Inc. (KTRA) stock is going down – Learn more about it!

    Kintara Therapeutics, Inc. (KTRA) has seen decrease of 1.13% in the premarket despite any news reported by the company. However, the last trading session closed at $0.354 with a decrease of 10.27%.

    Multiyear Research Grant – What’s up?

    KTRA announced on 12th January 2022 that Doctor Anna Golebiewska has been awarded with a multiyear research grant. This research grant is awarded by Luxembourg National Research Fund (FNR) and the Cancer Foundation Luxembourg. In Luxembourg, the FNR is the primary source of funding for research. Moreover, the Cancer Foundation Luxembourg is committed to patient assistance and oncology research by educating cancer patients.

    Now what?

    The acknowledgement and economic assistance from this prestigious organisation for VAL-083 research in Dr. Golebiewska’s laboratory is extremely exciting because it will offer critical data for optimising the clinical use of this first-in-class specific molecular chemotherapeutic. Furthermore, the findings of this study will aid in elucidating possible therapeutic targets for novel co – treatment regimens involving VAL-083, as well as promote the chance to improve therapeutic accuracy in GBM patients.

    First International Site Activation by KTRA – More About it

    On 30th November 2021, KTRA reported about the site activation in GCAR Phase 2/3 Clinical Trial. The speed with which the treatment arm will be implemented in the research continues to excite the Kintara team. Not only this but the company is thrilled to witness GCAR’s outstanding clinical testing consequences, which drew the team to participate in this exciting and highly efficient registrational study. With 31 sites already operational, including the first international site, the company is hopeful to observe GCAR’s extraordinary clinical trial execution capabilities.

    Through response adaptive randomization and a seamless Phase 2/3 design, GBM AGILE is a multinational, novel platform study that aims to find and confirm beneficial medicines for patients with GBM more quickly. The trial will be run under a master protocol that allows numerous medicines. Data from GBM AGILE might be utilized as the basis for new drug applicants and biologics licence applications. This has only been possible because of its novel design and efficient operational infrastructure.

  • What Do You Think Has Boosted KTRA Stock This Morning?

    As of the last check, shares of biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, Kintara Therapeutics Inc. (KTRA) were trading at $2.80, an increase of 23.35%. Kintara stock closed at $2.27 in the previous session. Volume for KTRA stock remained at 4.81 million shares, which is above the past 50 days’ average of 1.15 million shares.

    In the past week, KTRA shares have gained 1.34%, with this year’s performance of 230.04%. During a three-month period, KTRA stock gained 30.46%, and over a six-month period, it gained 71.97%. Additionally, KTRA has a current market capitalization of $74.68 million and still has 29.27 million outstanding shares. Following topline results from a phase 2 clinical trial, KTRA stock has been rising.

    Why did KTRA conduct the trial?

    Kintara, which has its headquarters in San Diego, California, focuses on the development of novel cancer therapies. In addition to VAL-083, KTRA is developing REM-001 for cutaneous metastatic breast cancer (CMBC), both of which are Phase 3-ready. A novel blood-brain barrier crossing, small molecule, bifunctional alkylating agent by KRTA, called VAL-083, has shown clinical activity against a variety of cancers. KTRA’s proprietary, late-stage photodynamic therapy platform, REM-001, demonstrates promise for localized cutaneous tumor treatment and for other potential applications.

    In its open-label, Phase 2 clinical study of its lead compound VAL-083, Kintara today announced topline data results from the recurrent arm.

    • The study was conducted by KTRA at the MD Anderson Cancer Center (MD Anderson) in Houston, Texas.
    • In Phase 2 of KTRA’s study, the treatment will be tested in patients with the unmethylated promoter of the methylguanine DNA-methyltransferase (MGMT) gene in glioblastoma multiforme (GBM) patients.
    • In the recurrent arm of the KTRA study, temozolomide was pre-treated prior to disease recurrence in patients with temozolomide pre-treatment.
    • A total of 89 patients were enrolled at KTRA, who were initially treated with 30 mg/m2/day on days 1, 2, and 3 of a 21-day cycle.
    • The 30 mg dose being examined is the same dose being tested in KTRA’s recently initiated and currently enrolling GBM AGILE study arm, VAL-083.

    An overview of the results:

    • The median overall survival (mOS) of the 48 efficacy-evaluable patients initially treated with 30 mg / m2 / day was found to be 8.0 months in the KTRA study.
    • Similary to KTRA’s prior research, the most frequent adverse event was myelosuppression.
    • Among patients receiving VAL-083 at 30 mg/m2/day, five experienced a serious adverse event (SAE) possibly related to the drug.
    • KTRA observed that mOS was 7.5 months for 83 efficacy evaluable patients who had completed at least one cycle of treatment.

    The FDA and European Medicines Agency have granted KTRA’s VAL-083 an Orphan Drug Designation for GBM. The FDA has also authorized Kintara (KTRA) to use it for the treatment of medulloblastoma and ovarian cancer, granting it Orphan Drug Designation for the same. Furthermore, KTRA’s VAL-083 in recurrent GBM has been given Fast Track Designation by the FDA.

  • What changed for these 50 stocks in Pre-Market Session?

    What changed for these 50 stocks in Pre-Market Session?

    Oncternal Therapeutics Inc. (ONCT) stock soared 2.42% to $2.96 in the pre-market trading as the company raised the size of the formerly publicized offering and purchase on a firm commitment basis 7,258,065 shares of common stock of the Company, at a price to the public of $3.10 per share, less underwriting discounts, and commissions.

    JOYY Inc. (NASDAQ: YY) shares are trading up 19.13% at $87.75 at the time of writing as the Company revealed its Q3, 2020 Earnings. Analysts have a consensus price target of $125. The company’s 52-week range was noted as $41.33 to $108.21.

    Aptevo Therapeutics Inc. (APVO) grew over 38.17% at $48.9 in pre-market trading today after the firm offered an update on ALG.APV-527, a novel immunotherapeutic bispecific candidate aimed for the cure of multiple solid tumors expressing 5T4, a tumor-restricted antigen.

    Zomedica Pharmaceuticals Corp. (ZOM), a Drug Manufacturers – Specialty & Generic company, dropped about -2.19% at $0.1428 in pre-market trading Thursday as the firm announced its Q3 2020 results.

    Nxt-ID Inc. (NXTD) stock moved down -1.99 percent to $0.35 in the pre-market trading after the Corporation declared to adjourn the annual meeting of shareholders.

    MoneyGram International Inc. (MGI) lost over -7.9% at $6.7 in pre-market trading Thursday 19 November 2020, as the company posted 150% year-over-year cross-border deal and revenue growth for October in its direct-to-consumer digital business, MGO.

    Lexicon Pharmaceuticals Inc. (LXRX) is up more than 2.5% at $1.64 in pre-market hours Thursday 19 November 2020 following the company revealed to participate in Stifel 2020 Virtual Healthcare conference on Wednesday, November 18, 2020. The stock had dropped over -11.60% to $1.60 in the last trading session.

    Before the trading started on 19 November 2020, UP Fintech Holding Limited (TIGR) is up 4.61% to reach $5.9 after the Company announced to unveil its quarterly results on November 25, 2020. It has been trading in a 52-week range of $2.03 to $7.60.

    Asia Pacific Wire & Cable Corporation Limited (APWC) stock plunged -4.72% to $2.02 in the pre-market trading as the Corporation publicized that it will organize its 2020 Annual General Meeting on September 18, 2020, at 9:00 a.m. New York time at its headquarters located at Room B, 15th Floor, No. 77, Section 2, Dunhua South Road, Taipei, 106, Taiwan and (2) the Company has procured a US$6,000,000 secured loan from its majority shareholder, Pacific Electric Wire & Cable Co., Ltd.

    Marathon Patent Group Inc. (NASDAQ: MARA) shares are trading down -0.35% at $2.88 at the time of writing following Bitcoin self-mining company has disclosed a new investor presentation, which contains updated economic information as of November 5, 2020. The company’s 52-week range was noted as $0.35 to $5.25. Analysts have a consensus price target of $8.

    Futu Holdings Limited (FUTU) grew over 10.7% at $47.6 in pre-market trading today after the company publicized its 3rd quarter scores.

    L Brands Inc. (LB), and Apparel Retail company, rose about 16.04% at $39.0 in pre-market trading Thursday as the firm announced upbeat earnings results.

    Agora Inc. (API) stock moved up 2.45 percent to $35.99 in the pre-market trading after the Tech-giant announced its Q3 2020 results.

    ObsEva SA (OBSV) gained over 3.38% at $2.14 in pre-market trading Thursday 19 November 2020 as the biotech-firm declared the positive topline results of PROLONG, the Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled trial of laropiprant in preterm labor.

    Bilibili Inc. (BILI) is up more than 4.49% at $50.0 in pre-market hours Thursday 19 November 2020, after the Corporation revealed its third-quarter 2020 results. The stock had dropped over -4.40% to $47.85 in the last trading session.

    Before the trading started on 19 November 2020, Youdao Inc. (DAO) is up 3.9% to reach $26.13, as it revealed quarterly results for the fiscal third quarter. It has been trading in a 52-week range of $13.20 to $47.70.

    Oragenics Inc. (OGEN) stock plunged -6.27% to $0.4377 in pre-market trading.

    SPI Energy Co. Ltd. (NASDAQ: SPI) shares are trading up 3.51% at $8.25 at the time of writing, as the Energy sector firm announced that its completely-owned SPI Solar, subsidiary completed the sale of a 1.015-megawatt solar project located on Hawaii’s Maui island. The company’s 52-week range was noted as $0.55 to $46.67.

    Gold Fields Limited (GFI) tumbled over -3.19% at $9.42 in pre-market trading today, following the Company revealed operational details for the 3-month period ending September 30, 2020.

    Marin Software Incorporated (MRIN), a Software – Application company, dropped about -3.38% at $2.0 in pre-market trading Thursday.

    X Financial (XYF) stock moved up 99.14 percent to $1.39 in the pre-market trading as the company disclosed that it will hold its 2020 annual general meeting of shareholders at its offices at 7/F, Block A, Aerospace Science and Technology Plaza, No.168 Haide Third Avenue, Nanshan District, Shenzhen, China on December 11, 2020, at 10:00 a.m., Beijing Time.

    Simon Property Group Inc. (SPG) lost over -2.43% at $74.75 in pre-market trading Thursday 19 November 2020 after the news that Simon has valued an upsized public offering of 19,250,000 shares of common stock at a public offering price of $72.50 per share that is expected to close November 23, 2020, subject to the satisfaction of customary closing conditions.

    ZoomInfo Technologies Inc. (ZI) is up more than 2.55% at $40.6 in pre-market hours Thursday 19 November 2020, as the Company revealed its Q3 2020 Earnings results. The stock had dropped over -2.85% to $39.59 in the last trading session.

    Before the trading started on 19 November 2020, Pan American Silver Corp. (PAAS) is down -2.98% to reach $29.98, after the Company Q3 results matched the predictions. It has been trading in a 52-week range of $10.61 to $40.11.

    Leap Therapeutics Inc. (LPTX) stock soared 6.67% to $1.6 in the pre-market trading, as the Company posted Q3 2020 Earnings results. The most recent rating by Piper Sandler, on June 29, 2020, is at an Overweight.

    Hudson Capital Inc. (NASDAQ: HUSN) shares are trading up 33.93% at $3.0 at the time of writing, following news of Hudson Capital Inc. and FreightHub, Inc. progressing further with the planned merger. The company’s 52-week range was noted as $1.60 to $9.80.

    Transocean Ltd. (RIG) grew over 4.07% at $1.28 in pre-market trading today, as the firm reported deep-water Corcovado, deep water Mykonos contract extensions.

    Acasti Pharma Inc. (ACST), a Biotechnology company, rose about 4.55% at $0.23 in pre-market trading Thursday, after the firm revealed Q2, 2021 fiscal results.

    Orbital Energy Group Inc. (OEG) stock moved up 3.56 percent to $0.8 in the pre-market trading, as the company posted Q3, 2020 earnings reports.

    Ideanomics Inc. (IDEX) gained over 10.34% at $1.28 in pre-market trading Thursday 19 November 2020 after the firm announced MEG October & Q4 sales activity.

    Virgin Galactic Holdings Inc. (SPCE) is up more than 2.04% at $23.05 in pre-market hours Thursday 19 November 2020 after the Analysts decreased its estimates by almost 25%. The stock had jumped over 5.81% to $22.59 in the last trading session.

    Before the trading started on 19 November 2020, Washington Prime Group Inc. (WPG) is down -2.15% to reach $0.742 after the report of the company to present at REITworld 2020 Virtual Investor Conference. It has been trading in a 52-week range of $0.49 to $4.49.

    Kintara Therapeutics Inc. (KTRA) stock soared 1.79% to $1.71 in the pre-market trading, after the company announced Q1, 2021 results and offered a business update.

    Electra Meccanica Vehicles Corp. (NASDAQ: SOLO) shares are trading up 7.53% at $7.43 at the time of writing. The company’s 52-week range was noted as $0.89 to $7.91.

    K12 Inc. (LRN) grew over 6.56% at $25.49 in pre-market trading today.

    Polar Power Inc. (POLA), an Electrical Equipment & Parts company, dropped about -3.35% at $3.46 in pre-market trading Thursday.

    Ayro Inc. (AYRO) stock moved up 3.77 percent to $4.4 in the pre-market trading, after the company revealed its Q3, 2020 fiscal results.

    Jaguar Health Inc. (JAGX) gained over 5.82% at $0.22 in pre-market trading Thursday 19 November 2020, following the announcement of its third-quarter 2020 financial scores.

    Sanchez Midstream Partners LP (SNMP) is down more than 0.0% at $0.5951 in pre-market hours Thursday 19 November 2020. The stock had jumped over 11.03% to $0.60 in the last trading session.

    Before the trading started on 19 November 2020, Waitr Holdings Inc. (WTRH) is up 6.46% to reach $3.38, as the company’s earnings results topped estimates. It has been trading in a 52-week range of $0.26 to $5.85.

    GreenPower Motor Company Inc. (GP) stock plunged -1.07% to $18.49 in the pre-market trading, after the report that Thermalito Union Elementary School District Agrees on purchase of six all-electric school buses from GreenPower. The most recent rating by Maxim Group, on November 02, 2020, is a Buy.

    Arcimoto Inc. (FUV) grew over 0.74% at $9.51 in pre-market trading today, after the company revealed its Q3, 2020 results, and business update.

    Kandi Technologies Group Inc. (KNDI), an Auto Manufacturers company, rose about 11.55% at $12.65 in pre-market trading Thursday, November 19, 2020, after the report that Kandi America’s EV qualified for $2,500 refund in Texas.

    China HGS Real Estate Inc. (HGSH) gained over 11.17% at $1.99 in pre-market trading Thursday 19 November 2020.

    VAALCO Energy Inc. (EGY) is down more than -9.63% at $1.22 in pre-market hours Thursday 19 November 2020, after the company revealed that it has signed a sale and purchase agreement to acquire Sasol Gabon S.A.’s 27.8% working interest in the Etame Marin block offshore Gabon. The stock had jumped over 32.35% to $1.35 in the last trading session.

    Before the trading started on 19 November 2020, Kazia Therapeutics Limited (KZIA) is down -7.87% to reach $12.41, as the announcement was made that it has executed a definitive contract with the International Coalition for Adaptive Research (GCAR) to commence Kazia’s participation in the GBM AGILE pivotal study in glioblastoma. It has been trading in a 52-week range of $2.47 to $11.10.

    Naked Brand Group Limited (NAKD) stock soared 39.0% to $0.18 in the pre-market trading.

    Phoenix Tree Holdings Limited (NYSE: DNK) shares are trading down -18.6% at $3.72 at the time of writing. The company’s 52-week range was noted as $1.27 to $13.90.